Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Public ClinicalTrials.gov record NCT05583227. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Patients With Eosinophilic Esophagitis (CROSSING).
Study identification
- NCT ID
- NCT05583227
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- AstraZeneca
- Industry
- Enrollment
- 368 participants
Conditions and interventions
Conditions
Interventions
- Placebo Other
- Tezepelumab Biological
Other · Biological
Eligibility (public fields only)
- Age range
- 12 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Not listed
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 9, 2022
- Primary completion
- Jul 13, 2026
- Completion
- Mar 22, 2027
- Last update posted
- Apr 20, 2026
2022 – 2027
United States locations
- U.S. sites
- 24
- U.S. states
- 20
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Phoenix | Arizona | 85016 | — |
| Research Site | Little Rock | Arkansas | 72202 | — |
| Research Site | Los Angeles | California | 90033 | — |
| Research Site | Aurora | Colorado | 80045 | — |
| Research Site | Inverness | Florida | 34452 | — |
| Research Site | Jacksonville | Florida | 32256 | — |
| Research Site | Saint Augustine | Florida | 32086 | — |
| Research Site | Normal | Illinois | 61761 | — |
| Research Site | Iowa City | Iowa | 52242 | — |
| Research Site | Topeka | Kansas | 66606 | — |
| Research Site | White Marsh | Maryland | 21162 | — |
| Research Site | Boston | Massachusetts | 02111 | — |
| Research Site | Chesterfield | Michigan | 48047 | — |
| Research Site | Lincoln | Nebraska | 68503 | — |
| Research Site | Ocean City | New Jersey | 07712 | — |
| Research Site | Brooklyn | New York | 11235 | — |
| Research Site | Chapel Hill | North Carolina | 27599 | — |
| Research Site | Cincinnati | Ohio | 45229 | — |
| Research Site | Philadelphia | Pennsylvania | 19104 | — |
| Research Site | Smithfield | Pennsylvania | 15478 | — |
| Research Site | Nashville | Tennessee | 37232 | — |
| Research Site | Houston | Texas | 77030 | — |
| Research Site | Salt Lake City | Utah | 84107 | — |
| Research Site | Salt Lake City | Utah | 84132 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 101 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05583227, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 20, 2026 · Synced Apr 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05583227 live on ClinicalTrials.gov.